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Abstract. Celiac disease (CD) is a multifactorial chronic inflammatory condition
that results in injury of the mucosal lining of the small intestine upon ingestion of
wheat gluten and related proteins from barley and rye. Although the exact
mechanisms leading to CD are not fully understood, the genetic basis of CD has
been relatively well characterized. In this review we briefly review the history of
discovery, clinical presentation, pathophysiology, and current understanding of
the genetics underlying CD risk. Then, we discuss what is known about the
current distribution and evolutionary history of genes underlying CD risk in light

	
  

of other evolutionary models of disease. Specifically, we conclude that the set of
loci underlying CD risk did not cohesively evolve as a response to a single past
selection event such as the development of agriculture. Rather, deterministic and
stochastic evolutionary processes have both contributed to the present distribution
of variation in CD risk loci. Selection has shaped some components of this
network, but this selection appears to have occurred at different points in the past.
Other parts of the CD risk network have likely arisen due to stochastic processes
such as genetic drift.

Celiac disease (CD) is a multifactorial chronic inflammatory condition that results
in injury of the mucosal lining of the small intestine. The earliest descriptions of
a condition with symptoms like CD date back to the first and second century
writings of the Greek physician Arataeus (Simoons 1981; Losowsky 2008). The
first modern description of CD is attributed to English physician Samuel Jones
Gee, who was familiar with the writings of Arataeus. In 1888 (Dowd and
Walker-Smith 1974; Simoons 1981; Losowsky 2008) Gee described the ‘coeliac
affection’ as a condition of chronic indigestion associated with diarrhea, wasting,
and weakness and common in people of all ages. Gee’s report was the first to
hypothesize dietary factors as a primary cause of the condition (Dowd and
Walker-Smith 1974), and during the early twentieth century some workers noted
the value of a starch free diet for prevention of CD (Haas 1924). Dicke and

	
  

colleagues (1950, 1953) observed the detrimental effect of wheat flour (but not
wheat starch) on CD patients experimentally confirming a role for diet as a driver
of CD. Shortly thereafter, Anderson and colleagues (Anderson et al. 1952; Alvey
et al. 1957) confirmed the effect of wheat on CD and identified wheat gluten as
the primary culprit.
CD appears to be an evolutionary paradox. Only since the 1950s have
clinicians recognized that a gluten-free diet is an effective treatment (Barker and
Liu 2008). Before that time, diagnosed and undiagnosed CD reduced the health
and fitness of sufferers, with juvenile cases leading to malnutrition or death, and
adult cases causing wasting, lack of adequate nutrition, greater susceptibility to
infection, and direct reductions in fertility (Corrao et al. 2001; Soni and Badawy
2010). Despite these apparent costs, CD is common today (>1%) in several
populations with long histories of wheat agriculture, including Europe, the Near
East, and North Africa (Catassi et al. 1996; Corrao et al. 1996; Mäki et al. 2003;
Rubio-Tapia et al. 2012). CD occurs at even higher frequencies in some parts of
these regions, reaching 5–6% among the Saharawi of northern Africa (Catassi et
al. 1999, 2001). There is little evidence that the present incidence of CD in these
populations can be explained by shifts in the environment, such as the “hygiene
effect” of lower pathogen and parasite loads that has been suggested to explain
increases in allergies and asthma. Both historical and archaeological evidence
show that CD was present in these populations before industrialization. Recent

	
  

diet shifts across much of this region have likely decreased the role of dietary
gluten, due to the adoption of maize, rice and other staple alternatives to wheat,
and more widespread use of refined flours with low gluten content.
The paradox of high CD incidence in these populations despite the evident
fitness costs seems to require some evolutionary explanation. Similarly, common
human disorders that have a fitness cost in one or more populations, such as
variegate porphyria, sickle-cell anemia, and cystic fibrosis, have been explained
either as a result of selective balances or founder effects. In contrast to such
examples, in which a single locus is implicated, CD is genetically complex. The
additive variance underlying CD risk can so far be attributed to more than 40
genetic loci identified in genome-wide association or case-control studies. The
strongest of these associations are in the Human Leukocyte Antigen (HLA) region
of the genome, which much evidence shows to be subject to recent natural
selection (Albrechtsen et al. 2010). But the larger network of more than 40 other
risk loci presents a potentially much more complex story than the well-known
single-gene examples of founder effects and balancing selection.
In this review we briefly cover the clinical presentation, pathophysiology,
and current understanding of the genetics underlying CD risk. Then, we discuss
what is known about the current distribution and evolutionary history of genes
underlying CD risk in light of other evolutionary models of disease.

	
  

Presentation, Pathophysiology, and Genetics of CD
Clinical Presentation and Treatment. The clinical presentation of CD is highly
variable and depends on age (Fasano 2005; Barker and Liu 2008). Classical
symptoms include abdominal pain and distension, diarrhea, malnutrition, and
failure to thrive within the first few years of life (Barker and Liu 2008). CD is
often recognized based on its characteristic damage to the mucosal lining of the
small intestine. The scoring system developed by Marsh (1992) ranges from
normal upper intestinal histology to increasing levels of crypt hyperplasia often
accompanied by intraepithelial lymphocytes and ending in any degree of villous
atrophy. Recent diagnoses have been assessed using the presence of tissue
transglutaminase (TGase) autoantibodies, such as immunoglobulin A (IgA), and
then confirmed after intestinal biopsy by response to treatment with a gluten-free
diet (GFD) (Farrell and Kelly 2002).
The complications of CD go far beyond the classical symptoms into other
aspects of biology and health. CD can cause vitamin (D and K) and micronutrient
(calcium, iron, folate) deficiencies, with prolonged cases often leading to
conditions such as rickets, osteoporosis, and anemia (Farrell and Kelly 2002;
Fasano 2005; Green and Cellier 2007). Linear enamel hypoplasias on the teeth, a
marker of nutritional stress, have been noted in greater than twenty percent of CD
cases in children (Bucci et al. 2007; Campisi et al. 2007; Cheng et al. 2010, but
see Procaccini et al. 2007, for a contrasting result). Neurological abnormalities

	
  

including hypotonia, developmental delay, learning disorders and ADHD,
headache, and cerebellar ataxia have also been reported to be more common in
children with CD (Zelnik et al. 2004). Patients with CD have a slightly increased
risk for developing gastrointestinal malignancies such as adenocarcinoma (Barker
and Liu 2008). As noted above, complications from CD may also include
reduced fertility and increased mortality (Corrao et al. 2001; Soni and Badawy
2010).
Celiac disease is unusually common among certain autoimmune disease
cohorts. Several researchers have noted a high occurrence of CD in patients
diagnosed with type 1 diabetes mellitus (T1DM) (Greco et al. 2012; Pham Short
et al. 2012). Increased prevalence of CD among autoimmune thyroid disease
sufferers has also been frequently noted (reviewed in Ch'ng et al. 2007). These
conditions share with CD an association with risk haplotypes HLA-DQ2 and
HLA-DQ8 (Ch'ng et al. 2007; Pham Short et al. 2012). In addition to T1DM,
shared (non-HLA) genetic risk factors with CD have been noted for Crohn’s
disease (CrD) (Festen et al. 2011) and rheumatoid arthritis (RA) (Zhernakova et
al. 2011).
The wide range of clinical symptoms and complications associated with
CD, particularly those that are more severe in children, support the interpretation
of CD as an evolutionary paradox. Prior to the recent discovery of gluten as the

	
  

primary environmental driver of CD, we might expect CD to have lowered
evolutionary fitness in individuals in the past afflicted with the condition.

Diet, HLA, and the Pathophysiology of CD. Celiac disease is activated by
proline-rich and glutamine-rich gluten proteins found in wheat and related
proteins in rye and barley (Kagnoff 2007), and in rare cases oats (Koning 2012).
Gluten is composed of two major protein types, gliadins and glutenins. The high
proline content of these peptides prohibits their complete digestion by gastric,
pancreatic, and brush border enzymes in the gastrointestinal tract (Shan et al.
2002). Once ingested, gluten is partially digested into large high-proline and
high-glutamine peptides, such as the 33 amino acid α-gliadin peptide, which can
accumulate in the small intestine.
Although wheat gluten and related proteins are clearly the primary
environmental trigger of CD, diet alone is not a sufficient explanation for the
occurrence of the disease (Green and Cellier 2007; Kagnoff 2007). The genetic
factors that influence pathogenesis of CD became evident and have been
confirmed by various family and twin studies of CD (Risch 1987; Petronzelli et
al. 1997; Bevan et al. 1999; Greco 2002; Nistico 2006). This work has securely
established HLA genes as the largest genetic components of CD risk. HLA
molecules are antigen-presenting molecules, which bind antigenic peptides and
present them to samples of circulating T-cells (Lawlor et al. 1990). More

	
  

precisely, with respect to the cell, HLA class I molecules bind endogenous
antigenic peptides and class II molecules bind exogenous antigenic peptides
(Townsend and Bodmer 1989; Lawlor et al. 1990). Although early findings
supported association to HLA class I alleles (Falchuk et al. 1972) and the class II
HLA-DR locus (DeMarchi et al. 1979), further research has demonstrated that CD
is most strongly associated with specific HLA class II alleles comprising HLADQ. Specifically, the alleles encoding the HLA-DQ2 and HLA-DQ8 molecules
are necessary, but not singularly responsible for CD risk. The majority of CD
cases (90–95%) are associated with the HLA-DQ2 heterodimer, which is encoded
by the alleles HLA-DQA1*05 and HLA-DQB1*02 either in cis, on the same
haplotype, or in trans (Sollid 1989; Sollid and Thorsby 1990; Spurkland et al.
1990). Additionally, a gene dosage effect has been observed for individuals
homozygous for HLA-DQB1*02 (Karinen et al. 2006; Murray et al. 2007). Of
the approximately ten percent of cases not carrying the HLA-DQ2 heterodimer,
half carry the HLA-DQ8 heterodimer (HLA-DQA1*03/HLA-DQB1*03:02) and
the other half carry either HLA-DQA1*05 or HLA-DQB1*02 alone (Karell et al.
2003). Further research has demonstrated the likely involvement of other genes in
the extended HLA region in CD risk (Margaritte-Jeannin et al. 2004; Ahn et al.
2012).
The role of the HLA-DQ2 and HLA-DQ8 heterodimers in CD
pathogenesis is well understood. HLA-DQ2 and HLA-DQ8 molecules contain

	
  

positively charged pockets, which preferentially bind to negatively charged
peptides. HLA-DQ heterodimers on antigen-presenting cells bind gluten peptides
in which glutamine has been deamidated (converted to negatively charged
glutamic acid) via tissue transglutaminase (Dieterich et al. 1997; Molberg et al.
1998; van de Wal et al. 1998; Fleckenstein et al. 2002; Fleckenstein 2004). The
bound gluten-HLA-DQ complexes are then presented to populations of CD4+ Tcells in the lamina propria of the small intestine. The T-cells that recognize the
gluten-HLA-DQ complexes then produce pro-inflammatory cytokines such as
interferon-𝛾, which likely play a role in the mucosal damage that is characteristic
of CD (Nilsen et al. 1998). Importantly, different wheat, rye, and barley each
contain a variable repertoire of immunogenic peptides. Not all CD patients
respond to the same sets of peptides (Koning 2012), which renders difficult the
development of non-immunogenic grains (Kagnoff 2007; Koning 2012).
In addition to the adaptive immune response described above, gliadin
peptides can also activate an innate immune response. This innate immune
response, which is characterized by an increase in the number of intra-epithelial
lymphocytes (IELs) in CD patients is probably related to ongoing pathogenesis of
CD such as the development of refractory CD (non-responsive villous atrophy
and malabsorption) and the development of enteropathy-associated T-cell
lymphoma (Kagnoff 2007). Interleukin-15 (IL-15) is up-regulated in the lamina
propria and the epithelium during the course of CD pathogenesis (Mention et al.

	
  

2003). The increased presence of IL-15 results in the activation of IEL’s
expressing the natural killer immunoreceptor NK-G2D. Activated IELs then
become cytotoxic and kill enterocytes with MIC cell-surface expression (Hüe et
al. 2004; Meresse et al. 2004; Green and Cellier 2007). For a more thorough
review of CD pathogenesis see (Green and Cellier 2007; Kagnoff 2007; Abadie et
al. 2011).

Non-HLA Genetic Factors: GWAS and Fine-Mapping Studies. Although
HLA comprises only 40% of the genetic variance of CD risk, no compelling nonHLA loci were shown to be associated with CD prior to the advent of genomewide association studies (GWAS) (Kumar et al. 2012). The first GWA study of
CD in 2007 (Van Heel et al.) included a cohort of 778 CD individuals and 1,422
controls from the UK. This study tested for association to approximately 310,000
single-nucleotide polymorphisms (SNPs) and identified a single risk locus in an
LD block harboring IL2-IL21. Two follow up studies on the same sample (Hunt
et al. 2008; Trynka et al. 2009) identified an additional nine non-HLA loci. A
later CD GWAS by Dubois and colleagues (2010) included over 4,500 CD cases
and over 11,000 controls from four populations (Finland, Italy, the Netherlands,
the UK). This study included replication of the 131 top SNPs in seven European
cohorts comprising approximately 5,000 CD cases and 5,500 controls and added
another 13 risk loci to the list of CD associated genomic regions. Importantly,

	
  

this study also demonstrated that nearly 50% of CD risk SNPs are in close
proximity to expression quantitative trait loci (eQTLs), suggesting a likely role for
changes in levels of gene expression in CD. As mentioned above, additional
GWA studies have identified risk loci shared between CD and other autoimmune
conditions such as T1DM, RA, CrD, and ulcerative colitis (UC) (Zhernakova et
al. 2007, 2011; Smyth et al. 2008; Barrett et al. 2009; Festen et al. 2009, 2011;
Cotsapas et al. 2011; Gutierrez-Achury et al. 2011). These studies have
illuminated the tremendously pleiotropic nature of loci underlying autoimmune
and other immune related conditions. For a comprehensive review of risk allele
sharing among autoimmune diseases, see Ricaño-Ponce and Wijmenga (2013).
A major step forward in the identification and resolution of risk loci
underlying CD was a fine-mapping study conducted by Trynka and colleagues
(2011). Rather than using the same genotype arrays as earlier CD studies, which
contained 300,000 to 550,000 SNPs ascertained primarily in Europeans and
dispersed throughout the genome, this study utilized the Immunochip (Cortes and
Brown 2011), a custom Illumina array designed to increase SNP coverage density
in regions with existing associations to 12 immune-mediated diseases (including
CD) in Europeans (~200,000 SNPs total). Trynka and colleagues (2011)
identified a total of 40 genomic loci (including HLA) associated with CD.
However, the additional resolution from the Immunochip array allowed the
researchers to identify multiple independent signals in 13 loci, for which alleles of

	
  

different SNPs in the same genomic region contribute independently to risk across
CD cases. This brought the total number of non-HLA CD associated loci to 39
with 57 independently associated SNPs and 29 signals confined to single genes.

Genetic Architecture and Heritability. A large proportion of risk for CD can be
attributed to genetic factors. The most recent large-scale twin-study of heritability
has estimated the narrow-sense heritability (h2) of CD at between 57% and 87%,
with variation in the h2 estimate due to the assumed population prevalence
(1/1000 and 1/91, respectively). (Nistico 2006). This estimate was not age
specific. Rather, mean age at diagnosis of twins in this study ranged from 0.5 to
57 years. However, 50% of twins were diagnosed before age three. Further, this
study did not explicitly control for the presence of gluten in the diet. The finemapping study by Trynka and colleagues (2011) has brought the total percentage
of that genetic variance currently explained to ~53.7%, with 40% due to the
primary HLA risk variants. Some combination of other effects likely explains the
remainder of the genetic variance that is expected from population data.
Traditional GWAS approaches are statistically underpowered to identify
causal rare-variants due to the fact that sample sizes needed to establish a
significant association with rare variants (MAF < 1%) are much larger than
needed for common variants (Gorlov et al. 2008). Further, traditional genotyping
arrays primarily consist of common variants. It has been proposed that rare-

	
  

variants may explain larger proportions of risk than common variants in certain
cases (Bodmer and Bonilla 2008; Asimit and Zeggini 2010), particularly those
that are population specific (Kumar et al. 2012). Therefore, although much of CD
risk can be explained by a common disease/common variant model, new methods
for identifying rare-variant associations hold the promise to discover additional
rare risk loci underlying this condition (Asimit and Zeggini 2010). Still,
widespread support for a major role of low-frequency variants remains
unsupported. The dense genotyping Immunochip analysis by Trynka and
colleagues (2011) identified lower frequency variants (< 5%) at four loci (CD28CTLA4-ICOS, PTPN2, RGS1, SOCS1-PRM1-PRM2), all of low effect size (OR
< 1.7). An exome sequencing study of a family of six segregating for CD failed to
identify any rare causal variants (Szperl et al. 2011). Finally, in a recent highcoverage exome sequencing study of 20 risk loci with overlapping associations to
six autoimmune diseases in 25 individuals, Hunt and colleagues (2013) estimate
that rare variants contribute to less than 3% of the heritability explained by
common variants at the risk loci included in the study. Though rare-variants in
coding regions appear to contribute little to disease risk, exploration of noncoding regions may prove more fruitful. The statistical factors making
identification of rare causal variants with larger effect sizes also make it
impossible for current GWAS approaches to identify common variants with very

	
  

small effect sizes. Doing so would require extremely large cohort sizes (Kumar et
al. 2012).
Further, traditional models used to estimate h2 from population occurrence
data typically assume that the trait does not involve gene-gene interactions
(epistasis). Failure to include epistasis in models of h2 where it does exist inflates
the estimate of h2 for the trait (Zuk et al. 2012). Recent developments in
identifying epistatic interactions (Rao et al. 2011; Ma et al. 2012; Rajapakse et al.
2012) hold promise for explaining some of the “missing” h2 underlying CD risk.

Environmental Risk Factors. The remainder of CD risk must lie in
environmental risk factors and gene by environment interactions. Although the
pathophysiology of CD is well understood, mysteries remain. For example,
environmental factors such as enteric viruses (Kagnoff 1984; Stene et al. 2006;
Kagnoff 2007) may in some cases affect the permeability of the mucosal lining of
the small intestine, allowing gluten peptides to access the underlying mucosal
layers. Additionally, variation in immunogenic peptides in wheat, rye, and barley
may explain some of the variation in CD symptoms (Koning 2012). A more
complete understanding of the non-genetic factors that contribute to CD will
improve our ability to study the evolutionary history of this condition.
While ingestion of gluten and related proteins are well established as the
driver of CD, the fact that such a small percentage of those with increased genetic

	
  

risk actually develop the condition suggests that other environmental triggers are
likely involved in the pathogenesis of CD.
Much focus has been placed on understanding the relationship(s) between
the human gut microbiota and disease pathogenesis (Fujimura et al. 2010).
Recently, study of the human gut microbiome has been applied to CD
pathogenesis (Sellito et al. 2012; Cheng et al. 2013; Sjöberg et al. 2013). Almost
a decade ago, Forsberg and colleagues (2004) noted the presence of rod-shaped
bacteria in CD patients, but not control, suggesting a potential role for bacterial
infection in breaking gluten tolerance in children. More recently, a prospective
study by Sellitto and colleagues (2012) tested the hypothesis that the entire gut
microbial ecosystem is involved in the switch from gluten tolerance to
autoimmune response in genetically susceptible individuals. The authors tracked
the changes in gut microbiome composition from birth to 24 months in 34 infants
with HLA-DQ2 and/or HLA-DQ8 risk genotypes and known to be first-degree
relatives of biopsy proven CD patients. The infants were randomly assigned to
two groups; one fed a gluten-free diet from 6-12 months, the other a glutenincluded diet. All infants resumed normal feeding at 12 months. The sample
included 13 infants from each group that completed all protocol, 8 infants from
each group were chosen randomly for final analysis. The researchers show a
significant increase in anti-gliadin antibodies (AGA), specifically
immunoglobulin G (IgG) in the early exposure group compared to the late

	
  

exposure group after normalizing by time of exposure. Additionally, they show
that the gut microbiota of at-risk infants were lacking in members of the phylum
Bacteroidetes and had higher abundance of the phylum Fermicutes, a composition
directly opposed to that of non at-risk infants. An earlier study by Palmer and
colleagues (2007) illustrated that in healthy infants, the microbial ecosystem
reaches a profile similar to that of adults within the first year of life. In contrast,
Sellitto and colleagues (2012) find that the gut microbiota of infants at risk for CD
maintain immature gut microbiota, characterized by low levels of Bacteroidetes
and high levels of Firmicutes, throughout the first two years of life. The authors
show that delayed exposure to gluten had an overall positive effect on prolonging
gluten tolerance and delaying onset of CD autoimmunity. They hypothesize that
the introduction of gluten in an immature gut microbiome could trigger the
development of autoimmunity.
In contrast, a slightly later study by Cheng and colleagues (2013) found no
significant differences in the overall composition and diversity of gut microbiota
(including Bacteroidetes) between a sample of 10 children with newly diagnosed
CD (aged 3–14) and 9 healthy controls (aged 4–16). Thus, the differences
observed by Sellitto and colleagues (2012) may not persist into later childhood.
Cheng and colleagues (2013), however, did identify a sub-population profile of
eight genus-like bacteria that differed significantly between the CD cases and
healthy controls.

	
  

Others have noted a relationship between gut bacteria and CD
development (Forsberg et al. 2004; Ou et al. 2009; Sanz et al. 2011; Sjöberg et al.
2013). Most recently, Sjöberg and colleagues (2013) demonstrate a relationship
between IL-17A, a proinflammatory cytokine involved in antibacterial defense,
gut microbiome composition, and CD pathogenesis. The authors suggest that
both gluten and CD associated bacteria, such as the rod-shaped bacterium
Lachnoanaerobaculum umeaense provoke IL-17A production in the intestinal
mucosa of CD patients. They argue that the magnitude of the IL-17A reaction to
gluten is largely influenced by the makeup of the gut microbiota, particularly the
amount of CD associated bacteria present. In line with the results of Sellitto and
colleagues (2012) mentioned above, these authors posit that conditions leading to
disturbances in the composition of the gut microbiota early in life can lead to
long-term dysbiosis with surpluses of CD associated bacteria. These abnormal
microbiota compositions may influence the amount of IL-17A responses to gluten
and constitute a major risk factor for contraction of CD in genetically at risk
children.
While investigation of the human gut microbiota has revealed a potential
role for variation in gut associated bacteria in CD development, the connection
between genes and environmental risk factors have provided no clear
understanding of the breakdown of gluten tolerance leading to downstream tissue
damage.

	
  

Fortunately, the primary environmental risk factor underlying CD risk
(gluten) is known, which makes CD a useful model for studying the evolutionary
genetics of complex disease, particularly within a biocultural evolutionary
framework. The well-understood history of grain domestication (Kilian et al.
2009; Willcox 2012) by humans gives us additional information that we can use
to illuminate the evolutionary history of CD. Several researchers have argued that
CD likely rose to its current frequency due to positive selection on risk variants
from some beneficial effect on the immune system within the context of
increasing human population density (Barreiro and Quintana-Murci 2010;
Zhernakova et al. 2010; Abadie et al. 2011). However, a more complex model of
CD may be necessary to explain the history of the full network of genes eliciting
the CD response.

Evolution of CD Risk
The CD Paradox. Knowledge of the worldwide prevalence of CD is incomplete
but growing (Gandolfi et al. 2000; Catassi et al. 2001; Mäki et al. 2003; Greco et
al. 2012; Riddle et al. 2012; Rubio-Tapia et al. 2012). Human populations
consume the cereals that can induce CD in widely varying amounts (Abadie et al.
2011). CD is more common among populations with European and Near Eastern
ancestry, even though these are precisely the populations with the longest history
of wheat, rye, and barley agriculture (Tresset and Vigne 2011; Zeder 2011).

	
  

Although the analogy is not entirely apt, we can contrast the pattern of CD with
the global pattern of lactose intolerance (lactase persistence), in which the
populations with the longest history of dairying and milk consumption are those
with the greatest adaptation to lactose digestion.
The population incidence of CD increases with age, but it is nonetheless
notable in children and young adults before and during the reproductive lifespan.
Mortality and morbidity associated with CD would have exerted fitness costs in
past populations. The persistence of CD therefore requires some explanation.
Several hypotheses present possible explanations:
1.

Founder effects in ancient populations might have increased the
frequency of deleterious CD risk alleles in at-risk populations.

2.

CD risk alleles may have been increased in frequency by positive
selection due to pleiotropic effects on other, non-CD phenotypes.

3. The genetic architecture of CD may be such that most loci
contributing to CD risk have only minor effects on risk, meaning
that selection against CD would have miniscule to nonexistent
effects on any single risk locus (Stranger et al. 2011).
4. Balancing or frequency-dependent selection may have maintained
some risk-associated variants at high frequencies in past
populations. In particular, it seems likely that either long-term

	
  

balancing selection, including overdominance, frequencydependent selection, or selection in a fluctuating (pathogen)
environment has led to the current distribution of HLA risk
variants in the ancestors of present at-risk populations
(Albrechtsen et al. 2010).

HLA and Balancing Selection. Balancing selection is a common evolutionary
mechanism underlying risk for many diseases in present populations. The classic
single-gene disease models with balancing selection are haemoglobinopathies,
structural abnormalities of globin proteins. The most famous case is sickle-cell
disease (Frenette and Atweh 2007), in which the sickle-cell gene has been
selected due to the advantage of heterozygous individuals in resisting malaria.
Recognition of this evolutionary history was facilitated by the geographic
association of hemoglobinopathies with historic malaria incidence, and the clear
fitness costs to homozygotes in both the presence and absence of malaria.
Much evidence supports the role of recent natural selection in shaping the
HLA region (Albrechtsen et al. 2010). Some HLA haplotypes have been
directionally selected in recent human populations, but there is no clear pattern of
directional selection on CD-risk-associated HLA haplotypes (Abadie et al. 2011).
HLA has long been observed to be under balancing selection in human
populations and ancestral hominins. In fact, many HLA Class II alleles pre-date

	
  

the divergence of all hominids (Humans & Apes) (Bergström and Gyllensten
1995). In fact, Bergström and Gyllensten (1995) found that DQB1 and DQA1 in
hominids possess some of the oldest polymorphism of all class II genes according
to the ratio of nonsynonymous to synonymous polymorphism at non-antigen
recognition site (ARS) codons. While the DQ loci appear to possess some of the
oldest allelic variation of all class II genes, they also maintain a relatively small
number of alleles indicating long-term balancing selection in hominids.
This pattern holds within the human species as well. In the largest
sequence study of the HLA complex in humans to date, Buhler and SanchezMazas (2011) analyzed 2,062 DNA sequences representing seven HLA genes (A,
B, Cw, DRB1, DQA1, DQB1, DPB1) in a sample of 23,500 individuals from 200
worldwide populations. The researchers found that DQA1 and DQB1 have the
highest percentage of significant Tajima’s D values across human populations.
DQA1 in particular has significantly positive values of Tajima’s D across nearly
every European sample in the study, suggesting the maintenance of allelic
variation due to some type of balancing or diversifying selection. Relative to
most other HLA loci, DQB1 alleles are less diverse in pairwise comparisons of
populations within regions. Buhler and Sanchez-Mazas (2011) suggest that this
lack of allelic diversity may reflect purifying selection on DQB1 due to structural
constraints on the formation of HLA-DQ heterodimers, but this hypothesis has yet
to be formally tested.

	
  

An earlier study by Solberg and colleagues (2008) found a similar result
after examining the Ewens-Watterson test of homozygosity in a large composite
global dataset of HLA allele frequencies to demonstrate that balancing selection is
widespread among HLA loci. The class II genes HLA-DQA1 and HLA-DQB1
are among the most strongly selected loci in this study, showing signals of
balancing selection in Europe, North Africa, and Southwest Asia, precisely where
CD is most common. The primary causal CD heterodimer (DQ2) is present at
substantial frequencies (>1%) in many populations worldwide but reaches
frequencies as high as 25% in populations of North Africa and Europe where CD
is most common (Traherne 2008; Gonzalez-Galarza et al. 2011). The relatively
high frequency of this heterodimer in Europeans may be, in part, due to recent
expansion of the COX long-range HLA haplotype approximately 25,000 years
ago (Smith et al. 2006; Traherne 2008).
Some researchers have argued that the cause of balancing selection in
HLA is overdominance (Takahata and Nei 1990; Takahata et al. 1992) within
environments with particular pathogen communities. Recent evidence pertaining
to this hypothesis is mixed. Balancing selection based on fitness overdominance
does not tend to increase identity-by-descent (IBD) in the region linked to a
selected locus, yet Albrechtsen and colleagues (2010) found strong IBD signals
for HLA. Strong IBD is itself a sign of selection, but is more likely produced by
fluctuating selection due to coevolution of immunity with pathogens, for example

	
  

in a frequency-dependent pattern. HLA risk alleles account for approximately
40% of the additive variance underlying CD risk, suggesting that balancing
selection may in part explain the occurrence of CD in European and North
African populations today.
Under this hypothesis, CD is a fitness-reducing side effect of selection
associated with pathogens. Bioarchaeological evidence demonstrates that dietary
and demographic transitions of the Holocene were detrimental to human health
(Larsen 2006). Dietary specialization led to nutritional deficits and denser living
conditions created ideal conditions for the spread of new pathogens, as
documented by higher rates of porotic hyperostosis, cribra orbitalia, dental caries,
linear enamel hypoplasias, tuberculosis, and trepanematoses in populations after
the onset of agricultural production (Armelagos and Harper 2005; Larsen 2006).
Genetic and archaeological evidence show the importance of adaptive evolution
concurrent with large-scale demographic change over the last 10,000 years
(Hawks et al. 2007). These observations provoke the hypothesis that the Holocene
transition to agriculture was a time of strong natural selection on genes important
to immunity. Providing that the genetic locus of largest effect in CD is HLA
(Trynka et al. 2011), and that genetic loci associated with autoimmune diseases in
general are enriched for long-range haplotype signals of recent positive selection
(Barreiro and Quintana-Murci 2010), a plausible hypothesis to explain the present
distribution of CD is that the recent shift in demography and settlement patterns in

	
  

human populations led to increased selection on immune-related genes due to
elevated pathogen pressure.

GWAS, Genetic Architecture, and Selection on Complex Traits. HLA is only
one component of the overall additive genetic variance in CD risk. A large
network of other loci is known to explain some of the additive variance. We refer
to these loci as “background risk” loci, because (a) each contributes to CD risk
only conditioned upon the presence of the major HLA risk alleles, and (b) each
makes only a small contribution to CD risk. The evolution of this set of loci may
have been shaped mainly by other phenotypic associations or by random genetic
drift, meaning that they may show very heterogeneous patterns of variation with
respect to each other. In order to discuss the evolution of background risk of CD,
we must more deeply probe the dynamics of this broader set of loci.
GWAS have provided nearly all the links between non-HLA loci and CD
risk. GWAS is an unbiased statistical approach to identify phenotype/allelic
correlations, with respect to genomic structure and the etiology of the phenotype
under consideration (Stranger et al. 2011). A major goal of GWAS is to provide
information about the underlying biology of a trait. Systems genetics approaches,
which analyze GWAS and other association data in combination with functional
genomics data, can be combined with database information approaches, such as
gene ontology (GO) (Botstein et al. 2000), gene-set enrichment analysis (GSEA)

	
  

(Subramanian et al. 2005) and similar types of analysis (Stranger et al. 2011), to
provide avenues for identifying the complete network that underlies a complex
trait.
At this point it is important to clarify the term “network.” CD risk loci that
have been identified by GWAS represent a network strictly in their joint
association with the CD phenotype. Pathway analysis can additionally examine
whether some or all of these genes interact via co-expression or co-involvement in
other phenotypes. In the case of CD, pathway analysis of GWAS loci has
facilitated the identification of several biochemical pathways underlying CD
including T-cells, NK-cells, B-cells, and neutrophils (Kumar et al. 2012), greatly
contributing to our understanding of CD pathogenesis. In that sense, different CD
background risk loci are parts of different functionally integrated networks of
genes, each related to a discrete biochemical pathway. Dietary gluten can, within
a certain biochemical context, have major effects on these different pathways, and
the pathogenesis of CD is modified by certain genes within those pathways. Yet
these pathways have many phenotypic consequences beyond CD, and many of the
genes in these pathways are not associated with CD risk. In that respect, the
functional integration of CD risk loci is unclear.
In contrast to functional integration, evolutionary integration provides an
alternative way of describing genetic systems. When different genes respond
together to a single environmental pressure, independent or semi-distinct

	
  

functional pathways may come to exhibit patterns of similarity, either in genetic
variation or differentiation. Evolutionary integration may be recognized by a
common pattern of evidence for positive selection, balancing selection, loss of
functional constraint, or differentiation among populations. Different populations
that share common environmental factors may also help to illuminate networks of
genes that respond to selection associated with similar environments (Hancock et
al. 2010a, 2010b, 2011).
To the extent that a trait involves related functional networks of genes,
both the environment and genetic architecture are necessary to drive evolutionary
integration. CD and other immune-related conditions tend to have at least one
locus contributing a majority of the genetic variance (HLA) in addition to many
other loci with small effect (Stranger et al. 2011; Kumar et al. 2012). This genetic
architecture of CD is similar to an exponential model of effect size, in which the
non-HLA loci make increasingly tiny contributions to the additive variance in
risk. HLA haplotypes account for approximately 40% of the additive genetic
variance of CD and the currently known non-HLA variants together account for at
most 14% (Trynka et al. 2011) (Figure 1). In this model, we expect that HLA
should bear the majority of the negative fitness effects of CD. Indeed, any
response to selection associated with CD will affect HLA genetic variation 40% /
14% = 2.86 times more than all of the other background loci combined.
Alternatively, if we consider that the largest contribution to cumulative

	
  

heritability of any single background locus is approximately 1%, then the
response to selection on HLA is approximately 40% / 1% = 40 times greater than
the response on the most heritable background locus.
We can conclude from these considerations that CD itself is unlikely to
have driven evolutionary integration of a network of associated loci. However, it
is implicit from the hypothesis that CD risk may be a side-effect of selection on
some other phenotype that evolutionary integration may have arisen on CD risk
loci from non-CD causes. The test of evolutionary integration is the pattern of
evolutionary history of CD risk-associated genes. If these genes exhibit a common
pattern of evolution, we may be able to discover which environmental or
historical factors generated the present pattern of CD risk. Alternatively, if the
evolutionary history of these loci has been heterogeneous, we may conclude that
CD is an accident of unrelated evolutionary causes.

Evolution of Non-HLA Risk Loci. We can evaluate the evolutionary history of
CD risk-associated loci by several methods. Some researchers (Pickrell et al.
2009; Barreiro and Quintana-Murci 2010; Zhernakova et al. 2010; Abadie et al.
2011) have used the iHS method to infer a role for strong recent selection on
some non-HLA GWAS risk loci in Europeans. For example, Zhernakova and
colleagues (2010) found evidence of recent selection in or around the genes
IL12A, IL18RAP, and SH2B3. The risk variant in the SH2B3 gene is functionally

	
  

involved in the NOD2 recognition pathway, suggesting that it may have been
positively selected to protect against bacterial infection. The authors inferred a
very recent onset of selection (between 1,200 and 1,700 years ago) by extended
haplotype homozygosity (EHH) (Sabeti et al. 2002). However, Sams and Hawks
(2013) found that this haplotype is present in the genome of Ötzi, the Tyrolean
Iceman, which dates to 5,300 years ago (Keller et al. 2012). The apparent
antiquity of the allele does not necessarily conflict with evidence for recent strong
selection, if a pre-existing rare allele was selected within the last 2,000 years, but
the apparent contradiction may also be explained by the wide variance in
estimates of time of onset of selection. A broader comparison of genes involved in
the CD risk network showed a low heterozygosity for these loci in the Ötzi
genome, suggesting that many of the risk loci most tightly associated with CD
risk today are not present in this ancient individual. Along these lines, Fumagalli
and colleagues (2011) show, after correcting for demography, that many nonHLA genes associated with autoimmune disease are significantly correlated with
pathogenic diversity. These genes include nine previously associated with CD
risk, further supporting a role for local adaptation to pathogens in shaping CD
risk.
While the past 10,000 years was a time of significant selection pressures
on the immune system, the present risk pattern of CD may also reflect earlier
events. Non-HLA regions of the genome associated with CD risk are more likely

	
  

to show significant differences between continents than are loci chosen randomly
from the genome (Sams and Hawks 2013). Genes contributing to CD risk stand
out against the overall genome-wide pattern of population structure, specifically
when comparing genetic samples from Europe against East Asia. Within
continents, African populations show relatively high differentiation of the CD risk
network compared to the genome-wide pattern. Two samples from China also
diverged more highly than the genome-wide expectation. These results point to
the possibility of selection affecting some of the genes that contribute to CD risk
today, at the time of differentiation of European and Asian populations, and again
within Africa. Although as noted above some loci show evidence based on iHS
for recent selection in Europe, this does not drive differentiation of CD risk genes
as a group relative to the rest of the genome (Sams and Hawks 2013). This
observation weakens the hypothesis that the broad network of CD risk loci has
experienced directional selection within the last 10,000 years, although
demographic factors might explain the lack of differentiation across European
populations. For example, if a significant portion of the ancestry of present
Europeans is found among early Neolithic Near Eastern agriculturalists as has
been predicted from archaeological and genomic data (Sokal et al. 1991; Haak et
al. 2010; Fu et al. 2012; Gamba et al. 2012; Pinhasi and Cramon-Taubadel 2012;
Sánchez-Quinto et al. 2012; Skoglund et al. 2012), CD risk loci may have been

	
  

selected early enough in the history of this demographic event to have spread to
all present European populations
These population comparisons point not to evolutionary integration of the
CD risk network, but instead to a heterogeneity of environmental influences in
past populations. The CD background risk network was affected by selection at
different times and in different populations, with no uniformity or consistency.
Further analysis of this pattern with explicit reference to effect sizes of CDassociated loci confirms the lack of systematic integration, as the signal of
selection at a CD-associated locus does not predict the effect-size of the locus on
present risk (Figure 2). Hence, although the joint association network underlying
CD risk in European populations today has not experienced the same selection
dynamics as the rest of the genome, these genes have responded to different
environments, not a single Neolithic pulse of adaptation. With respect to the
background of risk outside of the HLA system, CD is not an evolutionary
tradeoff.

Conclusions about CD Evolution. Celiac disease is a trait on the border
between simple and complex. Many risk loci are known, but one (HLA) accounts
for much more of the additive variance than others (Trynka et al. 2011). Given
the strong evidence of ongoing balancing selection at the HLA-DQA1 and HLA-

	
  

DQB1 haplotypes (cited above), HLA may explain the majority of the
evolutionary paradox of CD.
But this mechanism leaves much unexplained. The Saharawi of North
Africa, for example, have a 5.6% occurrence of CD, in comparison to 1–2% in
Southern Europe, despite similar frequencies of the primary risk HLA-DQ
haplotype (Catassi et al. 1999, 2001). What explains this difference in risk? In
contrast to many other populations of Europe and the Near East, wheat became a
staple food among the Saharawi only within the last century, and is now
introduced to the diet much earlier (in infancy) (Catassi et al. 2001). An intriguing
possibility is that selection on HLA-DQ may be have led to a balance between CD
risk and pathogen resistance after the spread of wheat, rye and barley agriculture
during the Neolithic. More refined analysis of HLA haplotypes in CD patients
from multiple combinations and tests for gene-gene interactions may reveal such
a pattern.
Non-HLA risk loci for CD show a much more complex pattern of
interactions between ancient environments and present-day risk. Some of these
loci do appear to have responded to selection on a recent timescale, but most
show no evidence of selection individually. While some parts of the CD risk jointassociation network are connected by protein–protein interactions (Figure 1), the
CD risk network as a whole consists of different functional biochemical pathways
(Kumar et al. 2012). Each may have been influenced by different environmental

	
  

and historical factors, and overall there is no evidence for evolutionary integration
among them. The pathogenesis of CD shows that the condition results from the
functional and regulatory activity of these loci. These were influenced by different
environmental pressures, at different times in human evolutionary history. Celiac
disease is a side effect of evolution, apparently in multiple ancient environments.
Its persistence despite the consumption of wheat in ancient human populations
may be attributed both to balancing selection on HLA class II alleles and the low
additive variance contributed by many other loci associated with CD risk. Other
autoimmune conditions share a similar pattern of risk dominated by HLA class II
variation and overlapping greatly with CD risk in many cases (Rioux et al. 2009;
Cotsapas et al. 2011; Gutierrez-Achury et al. 2011; Ahn et al. 2012; Cifuentes et
al. 2012). Celiac disease may provide a model for understanding the relations of
the present risk of autoimmune conditions to past human environments.
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Figure 1. Protein–protein interactions and effect-sizes among non-HLA celiac
disease risk loci. Protein–protein interactions among non-HLA CD risk loci
via the STRING (v.9.1) database (Franceschini et al. 2013), which is a
database of known and predicted protein interactions derived from multiple
contexts. Node colors reflect the number of independent associations to CD at
the locus centered on each gene (Yellow = 1; Blue = 2; Green = 3). Relative
node sizes reflect the total effect size of each locus, with independent signals
at each locus summed. Edge thicknesses reflect the confidence in each
interaction according to the STRING database.

	
  

Figure 2. Africa/Europe CD risk odds-ratio / FST test p-value rank order
correlation. Rank order correlation between Africa/Europe genome-wide FST test
p-values and CD risk locus odds-ratios reported by Trynka and colleagues (2011)
demonstrating the lack of correlation between these two variables. This pattern
suggests that CD loci with larger effect-sizes have not been systematically subject
to greater differentiation. The correlation coefficient is r2 = 0.268.

